Processa Pharmaceuticals, Inc.
PCSA· Nasdaq
PCSAProcessa Pharmaceuticals, Inc.
Filed Mar 29, 2024 · 10-K · 89 days after period end · 0001493152-24-011976
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | — |
| Net Income | -$2.40M | -$13.01M | -$3.18M | -$9.73M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Mar 29, 2024 · 89 d after period end
